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  ABSTRACT 
  Objective      To assess the impact of certolizumab pegol 
(CZP) on patient-reported outcomes (PROs) in rheumatoid 
arthritis (RA), and to interpret these results using number 
needed to treat (NNT), and associations between PRO 
responses and longer term outcomes.   
  Methods      A total of 619 patients with active RA were 
randomised to CZP 200 or 400 mg, or placebo plus 
methotrexate (MTX). PROs assessed included pain, 
patient’s global assessment of disease activity (PtGA), 
physical function, fatigue and health-related quality of life. 
Treatment impact on PROs, NNT to achieve simultaneous 
improvements in multiple PROs and correlations between 
PROs were calculated. Times to onset of improvements 
greater than or equal to minimum clinically important 
differences (MCIDs) in pain as a determinant of clinical 
outcomes at week 24 were compared between week 6 
and 12 responders, and in patients with improvements 
in pain ≥MCID at week 12 (week 12 responders/non-
responders).  
  Results      CZP 200 and 400 mg plus MTX were associated 
with rapid, clinically meaningful improvements in all PROs. 
The NNT for subjects to report changes ≥MCID in up 
to ﬁ  ve PROs was two to three, and ﬁ  ve for all six PROs 
(pain, PtGA, physical function, fatigue and short-form 
36-item Physical and Mental Component Summary 
Scores). More patients with improvements ≥MCID in 
pain at week 6 than those at week 12 had lower disease 
activity at week 24. Week 12 pain responders had better 
clinical outcomes at week 24 than non-responders.   
  Conclusions      The data demonstrate that CZP provides 
broad relief from the burden of RA.   
  Trial  registration  number    NCT00160602.      
  INTRODUCTION 
  With the advent of new biologic therapies in rheu-
matoid arthritis (RA), the goal of treatment has 
shifted to providing broad relief of physical, emo-
tional and social disease burdens. To understand 
symptom relief more broadly, the assessment of 
clinically meaningful improvements using minimal 
clinically important differences (MCIDs)    1    allows 
an understanding of the efﬁ  cacy of a new therapy 
in a more meaningful way. In addition to evaluat-
ing the impact of treatment on individual patient-
reported outcome (PRO) measures, MCIDs can be 
used in number needed-to-treat (NNT) or predic-
tive analyses to better understand the magnitude 
of treatment beneﬁ   t. The NNT determines the 
number of patients that need to be treated in order 
to obtain the beneﬁ  t of interest in one additional 
patient (small NNTs indicate a favourable treatment 
effect).    2    Additionally, the predictive value of MCIDs 
can be evaluated by examining whether achieving 
improvements ≥MCID earlier with active treatment 
result in better longer term clinical outcomes. 
  Certolizumab pegol (CZP), a PEGylated anti-
  tumour necrosis factor (anti-TNF) for the treatment 
of RA, has demonstrated efﬁ  cacy and safety in three 
phase III trials.    3–5    When administered with metho-
trexate (MTX), CZP provided rapid, sustained and 
clinically meaningful improvements in physical 
function, health-related quality of life (HRQoL) and 
all other PROs over 1 year.    6    To further extend these 
observations, data from the Rheumatoid Arthritis 
PreventIon of structural Damage (RAPID) 2 trial 
were examined to investigate the NNT based on 
patients reporting improvements ≥MCID, corre-
lations between individual PROs and other clini-
cal parameters, and times to onset of ‘responses’ 
(improvements ≥MCID) as predictors of disease 
activity at week 24.   
  METHODS 
    Patients and study design 
  Study methods of the RAPID 2 trial have been 
published previously.    5    Brieﬂ  y, patients with active 
RA (by 1987 American College of Rheumatology 
(ACR) classiﬁ  cation  criteria    7   ) with inadequate 
responses to MTX therapy were randomised 
to receive CZP (400 mg at weeks 0, 2 and 4 fol-
lowed by CZP 200 mg or 400 mg) plus MTX every 
2 weeks, or placebo plus MTX for 24 weeks. The 
study (NCT00160602) was conducted in accordance 
with good clinical practice and the Declaration of 
Helsinki. Institutional review boards or ethics com-
mittees approved the protocol at each centre, and 
all patients provided written informed consent.   
  Efﬁ  cacy assessments 
  The PROs were secondary efﬁ  cacy end points in 
RAPID 2, and included assessments of patient’s pain, 
global assessment of disease activity (PtGA), physi-
cal function, fatigue and HRQoL. Pain and PtGA 
were evaluated using 100 mm Visual Analogue 
Scales (VAS). MCIDs for pain and PtGA VAS are 
10 mm decreases from baseline.    8–13    Physical func-
tion was evaluated by the Health Assessment 
Questionnaire-Disability Index (HAQ-DI).    14        15    
MCID for the HAQ-DI is a 0.22-point decrease 
from baseline.    8        16    The Fatigue Assessment Scale 
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outcomes in patients reporting improvements ≥MCID in pain 
VAS at week 12 (pain week 12 responders) and those who did 
not (pain week 12 non-responders). As well as determination 
of LDA, DAS28 remission, achievement of patient acceptable 
symptom state (PASS, ≤1.04    24   ) or normative HAQ-DI scores 
(≤0.5    25        26   ) and rate of mTSS progression at week 24 were also 
assessed. Subjects without ACR20 responses at weeks 12 and 14 
were obligatorily withdrawn at week 16 and were not included 
in the analyses. Responder status was deﬁ  ned using last observa-
tion carried forward (LOCF)   imputation for LDA, DAS28 remis-
sion and HAQ-DI, and linear extrapolation for mTSS. Data from 
CZP 200 and 400 mg groups were combined for analysis.       
  RESULTS 
  Patients 
  Of 619 randomised patients (ITT population), 13% placebo, and 
71% and 74% CZP 200 mg-treated and 400 mg-treated patients, 
respectively, completed the study.    5    Mean age of the population 
was 52 years, 82% were female and mean disease duration was 
6.2 years. The burden of RA was signiﬁ  cant, evidenced by high 
baseline PRO scores (  table 1  ). Patients also reported markedly 
lower SF-36 domain scores compared with a US normative 
population without arthritis. The impact of RA on HRQoL was 
particularly evident in PF, RP, BP, GH and RE domains.   
    Impact of CZP on pain, PtGA, physical function, fatigue and 
HRQoL 
  CZP treatment was associated with reductions in pain, PtGA, 
HAQ-DI and fatigue as early as week 1, which were statisti-
cally signiﬁ  cant and clinically meaningful (≥MCID) compared 
with placebo (see online supplementary ﬁ  gure S1). CZP-treated 
patients also reported signiﬁ  cant improvements over placebo in 
overall HRQoL (SF-36) at the ﬁ  rst postbaseline assessment at 
week 12 (ﬁ  gure S1). 
  Reductions in pain, PtGA, improvements in physical func-
tion, fatigue and HRQoL were maintained until the end of study 
at week 24 (p<0.001) (  ﬁ  gure 1  ). At week 24, signiﬁ  cantly more 
patients in the CZP plus MTX groups reported improvements 
≥MCID in all six PROs (pain, PtGA, physical function, fatigue 
and PCS and MCS scores) (  ﬁ  gure 1F  ).   
  Improvements ≥MCID were evident in all eight SF-36 domain 
scores at week 12 for the CZP plus MTX groups, which were 
maintained until week 24 (  ﬁ  gure 2  ), with the largest improve-
ments at week 24 in the RP, BP and RE domains compared with 
baseline.   
  The beneﬁ  cial effects of CZP were similar between 200 and 
400 mg groups with no statistical signiﬁ  cance between groups 
in any PROs.   
    Analysis of NNT and correlations between individual PROs at 
week 24 (ITT population) 
  At week 24, 63% of CZP 200 mg plus MTX patients reported 
clinically meaningful improvements in one or more PRO com-
pared with 13% in placebo. Approximately 23% CZP plus 
MTX-treated patients reported clinically meaningful improve-
ments (≥MCID) in all six PROs compared with 3% in placebo. 
  NNT to achieve simultaneous clinically meaningful improve-
ments in one, two, three or four of six PROs was approximately 
two additional patients, and NNT to achieve improvements in 
ﬁ  ve of six PROs was three. NNT for improvements in all six 
PROs was approximately ﬁ  ve patients (  ﬁ  gure 3  ). Further analy-
ses were conducted to assess which of the six PROs was driv-
ing the increase in NNT to ﬁ  ve; indicating that patients were 
(FAS) was used to assess fatigue/tiredness. MCID for the FAS is 
10% of the scale range, corresponding to a 1-point decrease from 
baseline.    9        13    HRQoL was evaluated using the Medical Outcomes 
Survey short-form 36-item (SF-36), which assesses eight domains: 
Physical Functioning (PF), Role Physical (RP), Bodily Pain (BP), 
General Health (GH), Vitality (VT), Social Functioning (SF), Role 
Emotional (RE) and Mental Health (MH), scored from 0 to 100.    17    
Normalised and z-transformed domain scores are grouped into 
Physical and Mental Component Summary (PCS, MCS) Scores. 
PCS positively weights PF, RP, BP, GH and VT, whereas MCS 
positively weights VT, SF, RE and MH. MCIDs for SF-36 are 
deﬁ  ned as ≥5.0-point increases from baseline in domain scores 
and ≥2.5-point increases from baseline for PCS and MCS scores.    1    
    6        18    SF-36 domain scores were compared with US general popu-
lation norms speciﬁ  cally matched to the age and gender distri-
bution of the RAPID 2 trial population,    1        6        18    and displayed as a 
‘spydergram’.    19    
  SF-36 was completed at baseline and weeks 12 and 24. All 
other PROs were assessed at baseline, and weeks 1, 2, 4, 6, 8, 12 
and 24. Pain and physical function were also assessed at weeks 
16 and 20. 
  Clinical efﬁ  cacy assessments in RAPID 2 included the Disease 
Activity Score 28-joint count assessment-erythrocyte sedimenta-
tion rate (DAS28).    5    Low disease activity (LDA) was deﬁ  ned as 
DAS28≤3.2, and remission as DAS28≤2.6. Radiographs of the 
hands and feet were assessed using the van der Heijde modiﬁ  ed 
Total Sharp Score (mTSS).    5    Non-progression was deﬁ  ned as a 
change from baseline in mTSS ≤0.5. Clinical and Simpliﬁ  ed Disease 
Activity Indexes (CDAI and SDAI) were also calculated.    20      
  Statistical  analyses 
  Response  to  treatment 
  Analyses were conducted on the intent-to-treat (ITT) popula-
tion, which included all randomised patients. Further details are 
provided in the online supplementary material. 
  Post hoc comparisons of the proportion of patients report-
ing improvements ≥MCID for each PRO were performed using 
repeated-measures logistic regression with region, treatment, 
time and treatment by time interactions as factors and baseline 
scores as covariates.   
  NNT  and  correlations 
  Additional post hoc analyses were performed to calculate the 
percentage of patients reporting improvements ≥MCID in up to 
six PROs (pain, PtGA, HAQ-DI, fatigue, SF-36 PCS and MCS 
scores) in the active treatment arms (CZP 200 or 400 mg plus 
MTX) and placebo plus MTX group.    21        22    NNT was assessed 
using the following formula: NNT = 1/(response in active treat-
ment – response in placebo group). Missing data were imputed 
using non-responder imputation. 
  Correlations between PROs at week 24 were analysed using 
Pearson correlations, and interpreted as ≥–0.3 to ≤0.3 = low 
degree of correlation, >–0.6 to <–0.3 or >0.3 to <0.6 = mod-
erate degree and –1.0 to ≤–0.6 or ≥0.6 to 1.0 = high degree.    23    
Correlations between PROs and DAS28, mTSS, CDAI and SDAI 
were also assessed.   
  Predictive  analyses 
  To assess the predictive value of PROs on time to onset of 
response, two different analyses were performed. The ﬁ  rst was 
based on achieving LDA at week 24 in patients who had improve-
ments ≥MCID in pain at weeks 6 and 12 (week 6 responders), 
and those achieving these improvements at week 12 but not at 
week 6 (week 12 responders). The second analysis evaluated 
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at week 6 achieved LDA at week 24 compared with 16% of 
patients who were week 12 but not week 6 responders. 
  Of the 492 patients included in the ITT population, 414 and 
78 patients were classiﬁ  ed as pain week 12 responders and non-
responders respectively. More pain week 12 responders than 
non-responders had LDA (20.0% vs 3.9%) and remission (10.4% 
vs 1.3%) at week 24. Similarly, more week 12 responders had 
PASS (49.8% vs 39.0%) and normative HAQ-DI scores (23.4% 
vs 16.9%). The number of patients rated as mTSS non-progres-
sors at week 24 was comparable between week 12 responders 
and non-responders (80.9% vs 80.0%). At week 24, 77.1% and 
46.2% of week 12 responders versus non-responders remained 
in the study respectively.     
  DISCUSSION 
  In this report, data from the RAPID 2 trial conﬁ  rm that CZP pro-
vides broad relief of the multiple burdens imposed by RA. CZP 
was associated with rapid, clinically meaningful improvements 
in multiple PROs, observed as early as week 1, and maintained 
until study end at 6 months. These results mirror those observed 
in the RAPID 1 trial,    6    and data reported for other TNF inhibitors 
in randomised controlled trials,    1        18        27–31    although the rapid onset 
of action in all PROs observed with CZP (by week 1) has not 
been previously reported with the other agents.    1    
  To further demonstrate the beneﬁ  ts of CZP on PROs, improve-
ments ≥MCID in NNT and predictive analyses were used. Both 
methods can provide patients and physicians with meaningful 
information on treatment effect, such as how likely an individ-
ual patient is to beneﬁ  t from treatment with CZP and whether 
the level of response within the ﬁ  rst 12 weeks can determine 
longer term clinical outcomes. 
  To the authors’ knowledge, this is the ﬁ  rst study evaluating 
the beneﬁ  t of an anti-TNF in RA by calculating the NNT using 
a variety of PROs. Previous work has investigated the NNT for 
other TNF inhibitors based on clinical responses such as ACR 
20/50/70.    32–39    One study of TNF inhibitors (etanercept, inﬂ  ix-
imab or adalimumab), analysing NNT according to HAQ-DI, 
reported an NNT of 1.94.    37    In the present analysis, the NNT 
to achieve clinically meaningful improvements in up to ﬁ  ve 
of six PROs was similarly low; only two to three additional 
patients needed to be treated to have at least one patient report 
more likely to report clinically meaningful improvements in 
pain, PtGA, physical function, fatigue and SF-36 PCS than 
MCS. At week 24, of those CZP 200 mg plus MTX patients 
with improvements ≥MCID in ﬁ  ve of six PROs, 67% reported 
changes ≥MCID in SF-36 PCS and 47% in SF-36 MCS scores. 
In contrast, the majority of patients in the 200 mg group (95%) 
reported clinically meaningful improvements in the remaining 
four PROs (pain 96%; PtGA 98%, HAQ-DI 96%; fatigue 98%). 
Similar results were observed in the CZP 400 plus MTX group.   
  To further explore the increase in the NNT to achieve improve-
ments in all six PROs, correlation analyses between PROs and 
clinical parameters at week 24 were performed. These are pre-
sented for the CZP 200 mg plus MTX dose group, and were sim-
ilar in subjects receiving CZP 400 mg plus MTX. As suggested 
by the NNT results, there were moderate to high correlations 
between pain, PtGA, HAQ-DI and fatigue; with the highest 
observed between pain and PtGA and fatigue, and the lowest 
between HAQ-DI and fatigue (see online supplementary table 
S1). Correlations between SF-36 scores and other PROs were 
mostly moderate. High, negative correlations were observed 
between SF-36 BP domain scores and pain, VT and fatigue, and 
PF or PCS and HAQ-DI. MCS, RE and MH scores had the lowest 
negative correlations with HAQ-DI. No signiﬁ  cant correlations 
were observed between change from baseline in PCS and MCS 
scores at week 24 (p=0.888). As shown in the NNT analyses, 
MCS and mental domain scores had lower correlations with the 
rest of the PROs; thus including MCS scores increased the NNT 
from two to three patients to almost six patients. There were 
low correlations between DAS28, and MCS and mental domain 
scores. Similarly, correlations between change from baseline in 
mTSS and the various PROs or between mTSS and DAS28 were 
low.   
    Effect of time to onset of improvements in pain on clinical 
outcomes at week 24 (ITT population) 
  As pain is considered to be the most important symptom of RA 
and because of the excellent correlations found between pain 
and the other PROs, improvements ≥MCID in pain were inves-
tigated to determine their potential to predict outcomes at week 
24. In an analysis of week 6 and 12 responders, approximately 
27% of patients who reported improvements ≥MCID in pain 
  Table  1      Baseline  PRO  scores  
  PRO (mean (SD))   PBO+MTX  (n=127) 
  CZP 200 mg+MTX 
(n=246) 
  CZP 400 mg+MTX 
(n=246) 
Pain VAS (range 0–100 mm) 59.7 (22.2) 62.0 (19.3) 60.5 (20.1)
PtGA VAS (range 0–100 mm) 59.7 (21.9) 62.5 (20.3) 61.0 (19.6)
HAQ-DI (range 0–3) 1.6 (0.6) 1.6 (0.6) 1.6 (0.6)
Fatigue FAS NRS (range 0–10) 6.5 (1.8) 6.7 (1.9) 6.4 (1.8)
SF-36 (range 0–100)
  PCS 31.1 (6.7) 30.6 (5.9) 31.1 (6.3)
  MCS 40.1 (11.4) 38.6 (10.9) 39.6 (10.9)
 Domains
    Physical functioning 34.5 (21.4) 30.5 (20.0) 32.9 (20.0)
    Role physical 16.8 (27.8) 12.3 (24.4) 14.2 (25.7)
    Bodily pain 30.8 (16.9) 29.2 (14.3) 30.8 (14.7)
    General health 34.4 (15.8) 34.7 (15.5) 34.3 (14.7)
    Vitality 36.9 (18.7) 36.0 (17.7) 38.1 (17.2)
    Social functioning 48.8 (25.0) 46.2 (23.0) 49.3 (24.4)
    Role emotional 38.0 (41.6) 27.1 (39.3) 31.4 (38.7)
  Mental  health 53.5 (19.3) 52.1 (18.1) 52.9 (18.2)
      CZP, certolizumab pegol; FAS, Fatigue Assessment Scale; HAQ-DI, Health Assessment Questionnaire-Disability Index; ITT, 
intent to treat; MCS, mental component summary; MTX, methotrexate; NRS, numeric rating scale; PBO, placebo; PCS, physical 
component summary; PRO, patient-reported outcomes; PtGA, patient’s global assessment of disease activity; SF-36, short-form 
36-item health survey; VAS, Visual Analogue Scale.     
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  Further support for the use of all PRO measures including 
individual SF-36 domains to fully assess treatment beneﬁ  t is pro-
vided by the correlation analyses. There were high correlations 
between pain, disease activity, fatigue and physical function; 
however, these improvements were less well correlated with 
those reported for HRQoL. As expected, correlations between 
mTSS and the PROs or other clinical parameters were low. 
Physical function scores (HAQ-DI) showed strong correlations 
with SF-36 PF and PCS scores as expected, but also BP domain 
simultaneous relief in ﬁ  ve PROs, and the NNT for improve-
ments in all six PROs was ﬁ  ve to six patients. Further analy-
ses indicated that it was more difﬁ  cult for patients to achieve 
improvements ≥MCID in SF-36 PCS and more particularly MCS 
than in pain, PtGA, fatigue and physical function. This is not 
surprising as SF-36 measures additional aspects of the burden of 
RA and reporting improvements in complex concepts included 
in the mental component score implies a broader and holistic 
relief. 
  Figure  1          Adjusted mean change from baseline (SE) and percentage of patients reporting improvements ≥MCID in pain, PtGA, physical function, 
fatigue and health-related quality of life at week 24 (ITT population, LOCF). *p<0.001 for the CZP groups vs placebo. BP, bodily pain; CZP, certolizumab 
pegol; GH, general health; ITT, intent to treat; MCID, minimal clinically important difference; MCS, mental component summary; MH, mental health; 
MTX, methotrexate; PBO, placebo; PCS, physical component summary; PF, physical functioning; PtGA, patient’s global assessment of disease 
activity; RE, role emotional; RP, role physical; SF, social functioning; SF-36, short-form 36-item health survey; VT, vitality.    
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such as pep, motivation and energy. Therefore, although SF-36 
PCS and MCS scores provide a good summary metric of HRQoL, 
they do not fully reﬂ  ect the overall magnitude of changes within 
individual domains.    17        19    Physicians should consider data from 
all SF-36 domains as well as PCS and MCS scores in their deci-
sion-making process. To facilitate analysis and interpretation of 
treatment-related effects across the individual domains, ‘spyder-
grams’ were used to depict SF-36 results, which allowed a more 
global comparison of disease-related decrements in HRQoL ver-
sus normative data.    19    
  A limitation of the NNT analysis is that patients with active 
disease in the placebo plus MTX group were used as the com-
parator and, therefore, the analysis only relates to this compari-
son. Nevertheless, the low NNT conﬁ  rms the efﬁ  cacy of CZP 
regarding reported improvements in PROs, indicating that rela-
tively few patients need to be treated with CZP to achieve relief 
from the burdens of RA. 
  More patients with responses by week 6 had LDA at week 24 
than those with responses at week 12. Similarly, those patients 
achieving pain MCID by week 12 were more likely to have better 
and only moderate correlations with fatigue (FAS) scores and 
low correlations with SF-36 domains assessing MH. High corre-
lations were also observed between PF and BP, and between VT 
and SF and MH. Interestingly, strong correlations were observed 
between certain ‘physical’ and ‘mental’ domains (RP and RE; 
BP and SF). Evaluating treatment-associated changes across 
all PROs is thus a better method for assessing change in mul-
tidimensional function. Careful evaluation of all SF-36 domain 
scores offers more information than the summary scores alone. 
For example, correlations between FAS and SF-36 MCS scores 
were lower than those between FAS and SF-36 VT domain 
scores. As VT is one of the domains scored positively when cal-
culating MCS scores, these results indicate that the other three 
‘mental’ domains (SF, and particularly MH and RE) provide the 
greatest contribution to changes in SF-36 MCS scores. FAS had 
high/marked correlations with pain VAS and PtGA followed by 
VT, which could indicate that FAS and SF-36 VT scores provide 
complementary assessments for measuring fatigue/tiredness; 
FAS may be more appropriate to evaluate physical aspects of 
fatigue, whereas SF-36 VT more fully assesses mental aspects 
  Figure  2          Improvements in short-form 36-item (SF-36) domain scores (ITT population, LOCF). A. Spydergram of SF-36 domains at baseline and 
following treatment with CZP 200 mg. Scores were plotted from 0 (worst) to 100 (best) with demarcations along axes of the domains indicating 
changes of 10 points representing one to two times MCID. B. Percentage of patients reporting improvements ≥MCID in SF-36 domains at week 24; 
*p≤0.001; †p≤0.01. BP, bodily pain; CZP, certolizumab pegol; GH, general health; ITT, intent to treat; MCID, minimum clinically important difference; 
MH, mental health; MTX, methotrexate; PF, physical functioning; RE, role emotional; RP, role physical; SF, social functioning; VT,  vitality.    
A
B
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outcomes than those patients who did not achieve pain MCID 
at week 12, including LDA, remission and acceptable HAQ-DI 
scores. Taken together these results indicate that early improve-
ment in PROs predict both clinical and PROs at 6 months. They 
complement previous analyses from the RAPID 1 trial demon-
strating that patients who reported more rapid improvements in 
disease activity had higher chances of achieving better clinical 
outcomes at 1 year.    40    
  Overall, these results suggest that patients treated with CZP 
who achieve early responses according to either PROs or LDA 
have a greater chance of avoiding long-term disability. Because of 
the short 6-month study duration of RAPID 2, longer term data 
(1–2 years) are needed to conﬁ  rm the use of time to responses by 
PROs as a predictor of better clinical outcomes. 
  In conclusion, CZP 200 or 400 mg plus MTX administered 
every 2 weeks provides broad relief from the multiple burdens 
of RA. Signiﬁ   cant and clinically meaningful improvements, 
low NNTs and increased likelihood of achieving longer term 
outcomes with an earlier PRO response indicate that CZP is 
an effective treatment option, offering substantial beneﬁ  ts to 
patients.       
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